platinum has been researched along with Adenocarcinoma in 90 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (10.00) | 18.7374 |
| 1990's | 15 (16.67) | 18.2507 |
| 2000's | 11 (12.22) | 29.6817 |
| 2010's | 41 (45.56) | 24.3611 |
| 2020's | 14 (15.56) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, S; Singh, N; Walia, HK | 1 |
| Chang, JH; Chang, TH; Chen, WT; Chien, LN; Chou, YT; Chung, CL; Hong, SY; Hsiao, SH; Lin, SE | 1 |
| Boku, N; Chin, K; Ichimura, T; Kadowaki, S; Kitano, S; Kudo, T; Liu, J; Mitani, S; Muro, K; Ooki, A; Sakai, D; Satoh, T; Takashima, A; Thai, D; Yamaguchi, K; Zavodovskaya, M | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Li, C; Li, X; Shen, L; Wang, S; Wang, T; Zhai, J | 1 |
| Bandlamudi, C; Berger, MF; Chang, JC; Donoghue, MTA; Drilon, A; Gong, Y; Janjigian, YY; Mandelker, D; Murciano-Goroff, YR; Noronha, AM; Offit, K; Rosen, EY; Schram, AM; Stadler, ZK; Won, H; Yang, SR | 1 |
| Arai, D; Ito, K; Kaira, K; Kajiwara, T; Kobayashi, K; Kodama, H; Miura, K; Miyanaga, A; Mizutani, H; Mori, K; Nakamura, A; Ninomiya, T; Oba, T; Tamiya, M; Yamaguchi, O; Yanagitani, N | 1 |
| Albertella, MR; Bani, MR; Decio, A; Dellavedova, G; Formenti, L; Ghilardi, C; Giavazzi, R; Leo, E; Staniszewska, AD; Wilson, J | 1 |
| Bleckmann, A; Frost, N; Griesinger, F; Grohé, C; Janning, M; Kollmeier, J; Reck, M; Reinmuth, N; Sebastian, M; Thomas, M | 1 |
| Baak, JPA; Feng, J; Guo, H; Huang, X; Li, H; Zhu, L | 1 |
| Aoyagi, K; Boonstra, E; Cabral, H; Hong, T; Ono, R; Perkins, EJ; Quader, S; Sasaki, H; Tanabe, S; Yokozaki, H | 1 |
| Chen, G; Chen, J; Fan, Y; Fang, J; Gao, G; He, J; Hu, Y; Li, X; Lin, X; Shu, Y; Wang, Q; Wu, F; Zhang, Y; Zhao, J; Zhou, C; Zhu, X; Zou, J | 1 |
| Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W | 1 |
| Ramkissoon, S; Sorscher, S | 1 |
| Gao, H; He, K; Li, L; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, L; Wang, W; Xu, B; Yang, L | 1 |
| Ren, X; Wang, J; Wei, F; Xiong, Y; Zhao, N; Zheng, Y | 1 |
| Kasahara, K; Sone, T; Tambo, Y | 1 |
| Armstrong, AJ; George, D; Gupta, RT; Harrison, M; Healy, P; Humeniuk, MS; McNamara, M; Ramalingam, S; Wu, Y; Zhang, T | 1 |
| Agarwal, JP; Bhargava, P; Janu, A; Joshi, A; Kapoor, A; Mahajan, A; Noronha, V; Patil, VM; Prabhash, K; Zanwar, S | 1 |
| Gong, P; Ma, D; Ma, X; Wang, Y; Wei, Y | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Bara, RO; Byers, LA; Cardnell, RJ; Gay, CM; Heymach, JV; Johnson, FM; Ma, J; Sen, T; Su, X; Tong, P; Wakefield, C; Wang, J | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X | 1 |
| Hao, X; He, P; Hu, X; Li, J; Shi, Y; Wang, B; Wang, H; Wang, Y; Wang, Z; Yang, S; Yu, S; Zhang, X | 1 |
| Dzik, C; Guindalini, RS; Mak, MP; Takahashi, TK; Testa, L | 1 |
| Bellezza, G; Bennati, C; Cenci, M; Chiari, R; Crinò, L; Ferolla, P; Flacco, A; Giannarelli, D; Ludovini, V; Metro, G; Minotti, V; Puma, F; Rebonato, A; Ricciuti, B | 1 |
| Cai, Y; Chen, H; Gao, Z; Han, B; Jiang, G; Li, X; Lu, D; Qian, J; Su, B; Tan, X; Wang, J; Wang, S; Wu, Q; Yang, Y; Zhao, X | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Du, XJ; Li, YP; Liu, Y; Liu, YZ; Wang, J; Yang, XZ; Zhu, YH | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Alakus, H; Bollschweiler, E; Drebber, U; Eberz, PM; Frazer, KA; Harismendy, O; Hölscher, AH; Lowy, AM; Maus, M; Metzger, R; Mönig, SP; Siffert, W; Warnecke-Eberz, U | 1 |
| Fábián, K; Furák, J; Gyulai, M; Losonczy, G; Moldvay, J; Pápay, J; Podmaniczky, E; Puskás, R; Tímár, J; Tiszlavicz, L | 1 |
| Bierbach, U; Ding, S; Kucera, GL; Pickard, AJ | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Fang, C; Fu, Z; Jiang, H; Li, J; Lu, Q; Pei, Z; Wang, E; Wang, H; Wang, J; Wang, S | 1 |
| Anderson, MJ; Aust, D; Bailey, P; Barbour, A; Bassi, C; Biankin, AV; Bjerkvig, R; Bruxner, TJ; Chang, DK; Chantrill, LA; Chin, V; Chou, A; Christ, AN; Cloonan, N; Colvin, EK; Corbo, V; Cowley, MJ; Epari, K; Eshleman, JR; Fadlullah, MZ; Falconi, M; Fink, JL; Gill, AJ; Giry-Laterriere, M; Graham, JS; Grimmond, SM; Grützmann, R; Harliwong, I; Holmes, O; Hruban, RH; Humphrey, ES; Humphris, J; Iacobuzio-Donahue, CA; Idrisoglu, S; Jamieson, NB; Johns, AL; Jones, MD; Kassahn, KS; Kazakoff, SH; Kench, JG; Lawlor, RT; Lee, HC; Leonard, C; Maitra, A; Manning, S; Markham, E; Mawson, A; Merrett, ND; Miller, D; Morgan, RA; Musgrove, EA; Nagrial, AM; Newell, F; Nguyen, NQ; Niclou, SP; Nones, K; Nourbakhsh, E; Nourse, C; Pajic, M; Patch, AM; Pearson, JV; Pettitt, JA; Pilarsky, C; Pinese, M; Pinho, AV; Poudel, B; Quek, K; Quinn, MC; Robertson, AJ; Rooman, I; Samra, JS; Scarlett, CJ; Scarpa, A; Song, S; Steinmann, AM; Taylor, D; Tempero, MA; Toon, C; Tortora, G; Waddell, N; Wani, S; Wilson, PJ; Wolfgang, CL; Wood, S; Wu, J; Xu, Q; Zamboni, G; Zeps, N | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Abbassi-Ghadi, N; Begum, S; Biggs, J; Birkbak, NJ; Hanna, GB; Hochhauser, D; Horswell, S; Kumar, S; Matthews, N; McGranahan, N; Mitter, R; Murugaesu, N; Phillimore, B; Rowan, A; Salm, M; Swanton, C; Watkins, T; Wilson, GA | 1 |
| Bail, JP; Brigand, C; Collet, D; Gronnier, C; Lebreton, G; Luc, G; Mabrut, JY; Mariette, C; Meunier, B | 1 |
| Chen, YM; Lee, YC; Lin, YH; Perng, RP; Tseng, YC; Tseng, YH; Whang-Peng, J | 1 |
| Ames, T; Blanco, E; Corte-Rodríguez, M; Espina, M; Montes-Bayón, M; Sanz-Medel, A; Sierra, LM | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Gu, Z; He, Y; Hu, C; Li, Y; Xu, X; Zhang, X; Zhang, Z | 1 |
| Cohen, C; Hanley, KZ; Horowitz, IR; Khanna, N; Rubinsak, LA | 1 |
| Ding, X; Fei, K; Liu, D; Lu, Y; Su, B; Xu, W; Yang, Y | 1 |
| Cho, JH; Jang, TW; Kim, CS; Kim, HJ; Kim, HT; Kim, SK; Kim, YH; Kwak, SM; Lee, JE; Ryu, JS; Shin, ES; Yoo, YK; Yun, MH | 1 |
| Crysandt, M; Esser, A; Jost, E; Osieka, R; von Hobe, S; Wilop, S | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Bull, JM; Chan, D; Deng, W; He, G; Proett, JM; Rowe, RW; Siddik, Z; Strebel, FR | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Argiris, A; Ballas, MS; Belani, CP; Davies, A; Edelman, M; Gandara, DR; Gitlitz, BJ; Groshen, S; Hoffman, P; Koczywas, M; Liu, SV; Ramalingam, S; Tsao-Wei, DD; Vokes, EE | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Pavlidis, N | 1 |
| Cohen, J; Halm, EA; Mandeli, J; Mhango, G; Sigel, K; Strauss, G; Wisnivesky, J | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Correa, AM; Erasmus, JJ; Gold, KA; Heymach, J; Kalhor, N; Kim, ES; Lee, JJ; Munden, R; Papadimitrakopoulou, V; Pataer, A; Rice, DC; Swisher, SG; William, WN; Wistuba, II | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Guan, ZZ; Li, S; Xu, RH; Yuan, ZY | 1 |
| Cormio, G; Cuccovillo, A; Fattizzi, N; Loizzi, V; Selvaggi, L | 1 |
| Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK | 1 |
| Boxall, J; Collins, DJ; d'Arcy, JA; Lankester, KJ; Leach, MO; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, JN; Walker-Samuel, S | 1 |
| Brard, L; Kim, KK; Lange, TS; Shaw, SK; Singh, RK | 1 |
| Fujii, M; Horiuchi, M; Inuyama, Y; Kohno, N; Mashino, S | 1 |
| Bernard, JP; Fournel, P; Jorda, M; Laennec, E; Piperno, D; Rebattu, P; Souquet, PJ; Trillet, V | 1 |
| Ichii, M; Minami, T; Okazaki, Y | 1 |
| Hashii, K; Ichii, M; Kadota, E; Minami, T; Namikawa, K; Tateyama, I; Tohno, S; Tohno, Y; Utsumi, M; Yamada, MO | 1 |
| Barbé, V; Cassuto-Viguier, E; Creisson-Ducray, A; Etienne, MC; Ferréro, JM; Fischel, JL; Formento, P; Lagrange, JL; Milano, G; Mondain, JR | 1 |
| Adams, M; Fish, RG; Griffiths, H; James, K; Mason, M; Shelley, MD | 1 |
| Arimori, M; Furukawa, T; Ishibiki, K; Isobe, Y; Kase, S; Kubota, T; Kuo, TH; Saikawa, Y; Tanino, H; Watanabe, M | 1 |
| Murakami, T; Nagai, N; Ohama, K | 1 |
| Hirose, N; Nagashima, A; Nakahashi, H; Shimokawa, T; Yasumoto, K | 1 |
| Furukawa, T; Ishibiki, K; Kase, S; Kitajima, M; Kubota, T; Kuo, TH; Saikawa, Y; Tanino, H | 1 |
| Benard, J; Fajac, A; Llabador, Y; Moretto, P; Ortega, R; Simonoff, M | 1 |
| Hayashi, N; Ikeba, K; Kinoshita, K; Ohokubo, T; Sodemoto, T; Takagi, A; Takeda, S; Yamamoto, T | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Hamana, S; Ku, Y; Maruo, T; Miyahara, Y; Motoyama, S; Takeuchi, S; Tateiwa, Y; Yoshida, S | 1 |
| Aghajanian, C; Barakat, RR; Bhaskaran, D; Brown, C; Hensley, M; Hoskins, WJ; Markman, M; Revzin, M; Sabbatini, P; Smith, A; Soignet, S; Soslow, R; Spriggs, D; Venkatraman, E | 1 |
| Baumgartner, G; Cannon, PJ; Merrin, C; Wajsman, Z | 1 |
| Carr, DT; Coles, DT; Eagan, RT; Frytak, S; Ingle, JN; Kvols, LK; O'Fallon, JR; Rubin, J | 1 |
| Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M | 1 |
| Iakovlev, KI; Ivanov, VF; Konovalova, AL; Presnov, MA; Stetsenko, AI | 1 |
| Elliott, WL; Farrell, NP; Hoeschele, JD; Kraker, AJ; Sercel, AD; Showalter, HD | 1 |
| den Engelse, L; Los, G; McVie, JG; Pinedo, HM; Smals, OA; van der Vlist, M; van Vugt, MJ | 1 |
| Brann, TW; Frei, E; Herman, TS; Holden, SA; Khandekar, V; Korbut, TT; Rosbe, KW; Sotomayor, EA; Teicher, BA | 1 |
| Hayashibara, K; Hirosawa, A; Niitani, H; Tsuboi, E | 1 |
| Asano, M; Ebina, T; Ishigaki, H; Nara, K; Oh-ishi, S; Saitoh, S; Satoh, F; Satoh, S; Satoh, T; Yoshida, Y | 1 |
| Abad-Esteve, A; Fernandez, C; Monras, P; Moreno, I; Morera, J; Ribas-Mundo, M; Rosell, R; Ruiz, J | 1 |
| Boven, E; Elferink, F; Nauta, MM; Pinedo, HM; Schluper, HM; van der Vijgh, WJ | 1 |
4 review(s) available for platinum and Adenocarcinoma
| Article | Year |
|---|---|
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvant; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Stomach Neoplasms; Taxoids | 2022 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Two cases of endometrial cancer diagnosis associated with bone metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cervical Vertebrae; Cyclophosphamide; Diphosphonates; Doxorubicin; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Imidazoles; Middle Aged; Platinum; Spinal Neoplasms; Tibia; Zoledronic Acid | 2006 |
21 trial(s) available for platinum and Adenocarcinoma
| Article | Year |
|---|---|
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Japan; Matrix Metalloproteinase 9; Oxaliplatin; Platinum; Stomach Neoplasms | 2022 |
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Thyroid Nuclear Factor 1 | 2023 |
Pyrotinib in
Topics: Acrylamides; Adenocarcinoma; Adolescent; Adult; Aged; Aminoquinolines; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Young Adult | 2020 |
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brucea; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Emulsions; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phytotherapy; Plant Oils; Platinum; Prognosis | 2013 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Ethers, Cyclic; Female; Follow-Up Studies; Furans; Humans; Ketones; Lung Neoplasms; Macrolides; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatinine; Female; Fluorouracil; Humans; Korea; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum | 2006 |
Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Female; Genital Neoplasms, Female; Humans; Magnetic Resonance Imaging; Middle Aged; Pelvic Neoplasms; Platinum; Regional Blood Flow; Reproducibility of Results; Taxoids | 2007 |
[Results of a combination of platinum-vindesin-ametycin-bleomycin (CEMB) in the treatment of stage IV non-small-cell lung cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Platinum; Vindesine | 1993 |
A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count.
Topics: Adenocarcinoma; Aged; Carboplatin; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Male; Middle Aged; Monte Carlo Method; Ovarian Neoplasms; Platelet Count; Platinum; Risk Factors; Teratoma; Testicular Neoplasms; Thrombocytopenia | 1994 |
[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Platinum; Uterine Cervical Neoplasms; Vindesine | 1996 |
Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma: I. Analysis for pharmacokinetics, tumor response, and toxicity of platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Feasibility Studies; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoplasm Staging; Platinum; Uterine Neoplasms | 2001 |
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Galactitol; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Sugar Alcohols | 1977 |
Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammineplatinum and vindesine.
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Humans; Kidney; Lung Neoplasms; Platinum; Random Allocation; Thiosulfates; Time Factors; Vindesine | 1989 |
A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4'-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Podophyllotoxin; Random Allocation | 1987 |
65 other study(ies) available for platinum and Adenocarcinoma
| Article | Year |
|---|---|
Topics: Adenocarcinoma; Biomarkers; Case-Control Studies; Genotype; Humans; India; Methylenetetrahydrofolate Reductase (NADPH2); Pemetrexed; Platinum; Polymorphism, Genetic | 2022 |
Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Platinum; Survival Analysis | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
Topics: Adenocarcinoma; BRCA1 Protein; BRCA2 Protein; Germ Cells; Humans; Male; Mutation; Phenotype; Platinum | 2022 |
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Platinum; Ramucirumab; Retrospective Studies; Taxoids | 2023 |
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Topics: Adenocarcinoma; Animals; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Female; Heterografts; Humans; Mice; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Platinum | 2023 |
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Immediate-Early Proteins; MicroRNAs; Oxaliplatin; Platinum; Trypsin Inhibitor, Kazal Pancreatic; Tumor Microenvironment; Tumor Suppressor Proteins | 2023 |
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome | 2021 |
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Topics: Adenocarcinoma; BRCA2 Protein; Disease Progression; Germ-Line Mutation; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Platinum; United States | 2021 |
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Carboplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Pemetrexed; Peptides; Platinum; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inflammation; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Neutrophils; Pemetrexed; Platelet Count; Platinum; Prognosis | 2017 |
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Protein Kinase Inhibitors | 2017 |
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Topics: Adenocarcinoma; Aged; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Platinum; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Platinum; Young Adult | 2018 |
Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Treatment Outcome | 2018 |
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Aurora Kinase A; Cisplatin; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Small Cell Lung Carcinoma; Software | 2019 |
[Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2013 |
Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Male; Humans; Leucovorin; Male; Organoplatinum Compounds; Palliative Care; Platinum; Seminal Vesicles | 2014 |
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Platinum; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Survival Rate | 2014 |
Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Genotype; Haplotypes; Hematologic Diseases; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis | 2014 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Nude; Nanoconjugates; Platinum; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromogranins; Esophageal Neoplasms; Female; Follow-Up Studies; Genotype; GTP-Binding Protein alpha Subunits, Gs; Homozygote; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Survival Rate | 2014 |
Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Down-Regulation; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Platinum; Retrospective Studies; Sex Factors; Treatment Outcome | 2015 |
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Hydrolysis; Lung Neoplasms; Platinum; Prodrugs; Valproic Acid | 2014 |
Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; MyoD Protein; Myoglobin; Myosin Type II; Platinum; Pleural Effusion, Malignant; Prognosis; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2015 |
Whole genomes redefine the mutational landscape of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; DNA Mutational Analysis; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Genetic Markers; Genome, Human; Genomic Instability; Genomics; Genotype; Humans; Mice; Mutation; Pancreatic Neoplasms; Platinum; Point Mutation; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays | 2015 |
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyclooxygenase 2; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2015 |
Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Computational Biology; DNA Copy Number Variations; Esophageal Neoplasms; Evolution, Molecular; Exome; Gene Amplification; Genetic Variation; Genome, Human; Genomic Instability; Genomics; Humans; Mutation; Neoadjuvant Therapy; Platinum | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; France; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2015 |
Supramolecular PEGylated Dendritic Systems as pH/Redox Dual-Responsive Theranostic Nanoplatforms for Platinum Drug Delivery and NIR Imaging.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Fluorescent Dyes; Heterografts; Humans; Hydrogen-Ion Concentration; Infrared Rays; Mice; Nanoparticles; Oxidation-Reduction; Platinum; Theranostic Nanomedicine; Treatment Outcome | 2016 |
Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Folate Receptor 1; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Ovarian Neoplasms; Platinum; Uterine Cervical Neoplasms | 2018 |
Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Caspase 8; China; Disease-Free Survival; Female; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Quality of Life | 2017 |
Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prognosis; Ubiquitin-Protein Ligases | 2008 |
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; DNA Adducts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Hyperthermia, Induced; Organoplatinum Compounds; Oxaliplatin; Platinum; Rats; Rats, Inbred F344; Treatment Outcome | 2010 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasms, Unknown Primary; Platinum; Prognosis; Taxoids; Treatment Outcome | 2012 |
Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; SEER Program; Survival Rate | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2013 |
[Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin].
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione Transferase; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Oncolytic Viruses; Platinum | 2005 |
A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.
Topics: Adenocarcinoma; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Indoles; Isocyanates; Male; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Pancreatic Neoplasms; Platinum; Prostatic Neoplasms | 2008 |
[Pharmacokinetics of cis-dichlorodiammineplatinum (II)].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Kinetics; Platinum; Spectrophotometry, Atomic | 1982 |
Comparison of three different methods for measurement of tissue platinum level.
Topics: Adenocarcinoma; Animals; Cadmium; Cisplatin; Female; Humans; Injections, Intravenous; Kidney; Lumbar Vertebrae; Male; Mass Spectrometry; Mice; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Tissue Distribution | 1995 |
Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin.
Topics: Adenocarcinoma; Cisplatin; Female; Humans; Intervertebral Disc; Isotope Labeling; Lumbar Vertebrae; Mass Spectrometry; Ovarian Neoplasms; Platinum | 1994 |
Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them.
Topics: Adenocarcinoma; Cell Survival; Cisplatin; Drug Overdose; Female; Humans; Lung Neoplasms; Middle Aged; Platinum; Renal Dialysis; Renal Insufficiency; Tumor Cells, Cultured | 1994 |
Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Platinum; Stomach Neoplasms; Time Factors; Transplantation, Heterologous | 1994 |
[Distribution of platinum in the female genital tract after intraarterial carboplatin infusion during the operation of uterine cervical cancer].
Topics: Adenocarcinoma; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Genitalia, Female; Humans; Infusions, Intra-Arterial; Intraoperative Care; Lymph Nodes; Platinum; Uterine Cervical Neoplasms | 1994 |
Pharmacokinetics of cisplatin instilled into the pleural cavity following panpleuropneumonectomy in patients with malignant pleurisy due to lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Instillation, Drug; Lung Neoplasms; Male; Middle Aged; Platinum; Pleura; Pleural Effusion, Malignant; Pleurisy; Pneumonectomy; Prognosis | 1993 |
Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Humans; Mitomycin; Platinum; Stomach Neoplasms; Tumor Cells, Cultured | 1993 |
Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Spectrometry, X-Ray Emission; Trace Elements; Tumor Cells, Cultured | 1996 |
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.
Topics: Adenocarcinoma; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Platinum; Remission Induction | 1999 |
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Intraoperative Care; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies | 2002 |
Nonhormonal chemotherapy for disseminated renal cell carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Female; Humans; Kidney Neoplasms; Lomustine; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Platinum | 1976 |
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Hybridization, Genetic; Hydroxyurea; Lomustine; Male; Methotrexate; Neoplasms, Experimental; Platinum; Prostatic Neoplasms; Rats | 1978 |
[Antineoplastic properties of complex compounds of platinum(II)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; L-Lactate Dehydrogenase; Leukemia L1210; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Platinum; Syndrome | 1976 |
Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; Diamines; Drug Resistance; Humans; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Malonates; Mammary Neoplasms, Experimental; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Platinum; Structure-Activity Relationship; Tumor Cells, Cultured | 1992 |
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Topics: Adenocarcinoma; Animals; Body Temperature; Carboplatin; Colonic Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Injections, Intraperitoneal; Injections, Intravenous; Male; Peritoneal Neoplasms; Platinum; Rats; Tissue Distribution | 1992 |
Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
Topics: Adenocarcinoma; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; DNA; Drug Resistance; Glutathione Transferase; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Platinum; Sulfhydryl Compounds; Tumor Cells, Cultured | 1991 |
[An autopsy case of rectal cancer receiving cisplatin at total dose of 3.250 mg and platinum concentrations in autopsy tissue samples].
Topics: Adenocarcinoma; Cisplatin; Colon; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Platinum; Rectal Neoplasms; Spleen; Tissue Distribution | 1989 |
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Brain; Cell Line; Cisplatin; Female; Kidney; Liver; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Ovarian Neoplasms; Platinum | 1985 |